A minimally invasive procedure to repair a leaky tricuspid valve significantly reduced hospitalizations for heart failure and improved outcomes for patients over a two-year period, according to research presented this week at the American College of Cardiology’s Annual Scientific Session. The findings offer renewed hope for individuals suffering from tricuspid regurgitation, a common heart condition that often goes undiagnosed and can severely impact quality of life.
The study, led by Dr. Erwan Donal of Rennes University Hospital in France, demonstrated that patients receiving transcatheter tricuspid edge-to-edge repair (T-TEER) – a procedure involving a clip to mend the valve – experienced a 40% reduction in heart failure-related hospitalizations compared to those receiving optimal medical therapy alone. This translates to fewer emergency room visits, shorter hospital stays, and a better overall prognosis for a vulnerable patient population.
Tricuspid regurgitation occurs when the tricuspid valve, located on the right side of the heart, doesn’t close properly, allowing blood to leak backward into the right atrium. This forces the heart to work harder to pump blood effectively, leading to symptoms like fatigue, shortness of breath, and swelling in the legs and abdomen. It’s estimated that tricuspid regurgitation affects millions, and is more common in women than men, often developing as a consequence of other heart or lung conditions.
A New Approach to a Challenging Condition
Currently, the standard treatment for tricuspid regurgitation focuses on managing symptoms with diuretics to reduce fluid buildup. But, diuretics don’t address the underlying valve defect. T-TEER offers a different approach, providing a less invasive alternative to open-heart surgery. The procedure involves inserting a catheter – a long, thin tube – through a vein to deliver a clip that brings the valve leaflets together, reducing the leak.
The TRI-FR trial, conducted across 24 centers in France and Belgium, enrolled 300 patients with severe, symptomatic tricuspid regurgitation. The average age of participants was 78, and a significant majority (63.7%) were women. Notably, 91% of the participants also had atrial fibrillation, a common heart rhythm disorder, and 70% had high blood pressure despite being on medication. Forty percent had been hospitalized for heart failure in the year prior to enrollment, highlighting the severity of their condition.
What sets this study apart from previous research on T-TEER is its design. Unlike earlier trials, the TRI-FR trial prevented patients in the control group from “crossing over” to receive the T-TEER procedure during the study period. This was due to the French national health insurance system not covering the cost of the TriClip device used in the trial. “Without the confounding effect of crossover, , among patients with very severe tricuspid regurgitation, T-TEER improved not only quality of life but also patients’ long-term outcomes,” explained Dr. Donal in a statement released by the American College of Cardiology.
Key Findings and Long-Term Implications
At the two-year follow-up, 19.7% of patients in the T-TEER group experienced a primary endpoint event – a composite measure including heart failure severity, quality of life, and major cardiovascular events – compared to 34.5% in the control group. The most significant finding was the 40% reduction in hospitalizations for worsening heart failure in the T-TEER group (13.8% vs. 23%).
These results complement findings from the TRILUMINATE trial conducted in the United States, which did allow for crossover. Dr. Donal emphasized that the TRI-FR trial provides valuable complementary evidence, being the first randomized study to report outcomes beyond two years without crossover between treatment groups.
The research team is now analyzing the cost-effectiveness of T-TEER in conjunction with standard medical care. They also plan to continue following the patients for a total of five years to determine if the procedure leads to increased longevity. A limitation of the study, as acknowledged by Dr. Donal, is that it was “unblinded,” meaning both patients and clinicians were aware of who received the T-TEER procedure.
What This Means for Patients
For patients struggling with severe tricuspid regurgitation, the TRI-FR trial offers a promising new avenue for treatment. While not a cure, T-TEER appears to significantly improve symptoms and reduce the burden of heart failure, potentially leading to a better quality of life and fewer hospitalizations. It’s important to note that T-TEER is not suitable for all patients, and a thorough evaluation by a cardiologist is necessary to determine if it’s the right option.
The study was funded by the French Ministry of Health, with additional support from Abbott Vascular, the maker of the TriClip device. Dr. Donal presented the findings on March 29th at the ACC.26 conference in Atlanta, Georgia.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The ongoing research into T-TEER and other minimally invasive valve repair techniques represents a significant step forward in the treatment of heart failure. Researchers will continue to monitor the long-term effects of the procedure and explore its potential benefits for a wider range of patients.
Have you or a loved one been affected by tricuspid regurgitation? Share your thoughts and experiences in the comments below, and please share this article with anyone who might find it helpful.
